Produces Cobalt-60 in Ontario reactors, sterilizes medical devices with it, and certifies that sterilization for FDA filings.
What stands out
- Returns appear driven by leverage
At a glance
Produces Cobalt-60 in Ontario reactors, sterilizes medical devices with it, and certifies that sterilization for FDA filings.
What this company is and how it runs — written from structure, not news.
Sotera Health produces Cobalt-60 inside nuclear reactors at Ontario facilities licensed under Atomic Energy of Canada Limited, loads that isotope into Sterigenics sterilization chambers to irradiate medical devices, and then certifies sterility through Nelson Labs testing — with the dose map and test records from each specific chamber written directly into customers' FDA submissions. Because that validated chamber configuration is what regulators have approved, switching to a different facility means revalidating the dose map and updating the regulatory filing, which makes the cost of leaving high enough that most customers simply don't. The Cobalt-60 sources themselves decay on a fixed 5.27-year half-life, so customers must replace them on a schedule set by physics, and each replacement goes back to whoever supplied the original source. The whole structure depends on the Ontario reactors staying licensed and operational — if Canada curtails the reactor program or restricts isotope exports, the feedstock that every sterilization chamber in the industry requires disappears, and there is no non-reactor alternative that can replace it.
How does this company make money?
The company charges customers a per-cubic-foot fee each time it sterilizes a batch of medical devices or pharmaceuticals. It also sells Cobalt-60 sources directly, and because those sources decay on a fixed 5.27-year half-life, customers must buy replacements on a schedule set by physics — making each sale a repeat purchase that cannot be deferred. Nelson Labs charges per-test fees for the laboratory work that goes into regulatory compliance documentation.
What makes this company hard to replace?
The dose map validated inside a specific Sterigenics chamber is the one named in a customer's FDA submission. Switching to a different facility means that map must be revalidated and the regulatory filing updated — a costly and time-consuming process. Nelson Labs' testing history is also embedded in those same submissions, so changing testing providers adds another layer of supplemental documentation. On top of that, Cobalt-60 source placement contracts run for multiple years because the replacement schedule is set by radioactive decay — sources lose half their strength every 5.27 years — not by anything the customer controls.
What limits this company?
Cobalt-60 can only be made inside a nuclear reactor, and the reactors that produce it at commercial scale are the Ontario facilities operating under Atomic Energy of Canada Limited. Increasing output means getting new or expanded licenses from the Canadian Nuclear Safety Commission, a process that takes years regardless of how much money is available. Capital cannot buy more reactor-time, and reactor-time is the only thing that makes more Cobalt-60.
What does this company depend on?
The company cannot operate without Canadian Nuclear Safety Commission licenses that permit Cobalt-60 production at the Ontario reactors, and without the Atomic Energy of Canada Limited reactor infrastructure those licenses cover. It also depends on FDA radiation sterilization dose validation protocols to make its sterilization records count in regulatory filings, on International Atomic Energy Agency transport certifications to legally ship radioactive isotopes, and on specialized lead-lined transport casks to physically move Cobalt-60 sources between facilities.
Who depends on this company?
Medical device manufacturers whose FDA 510(k) submissions name a specific Sterigenics chamber configuration depend on the company to keep that chamber running — if they switched sterilization providers, they would have to revalidate everything and file supplemental documentation with the FDA. Single-use medical product companies whose sterility claims are tied to validated dose maps at specific Sterigenics facility layouts face the same problem. Pharmaceutical companies making drug-device combination products where the radiation dose is part of the product specification cannot simply move to a different sterilization provider without re-establishing those dose levels from scratch.
How does this company scale?
Producing more Cobalt-60 from reactors that are already running costs relatively little, because the reactors' operating costs are mostly fixed whether utilization is high or low. The same is true for processing more devices through existing Sterigenics chambers. What does not scale cheaply is adding capacity: building new shielded sterilization facilities or expanding reactor output both require multi-year nuclear licensing processes that extra investment cannot speed up.
What external forces can significantly affect this company?
Changes to Canadian federal nuclear policy could affect whether the Ontario reactors keep operating and whether isotope exports remain permitted. International shipping regulations for radioactive materials can restrict or complicate the routes used to move Cobalt-60 sources around the world. And as medical device regulators in different regions — the FDA, the European Medicines Agency, and others — work toward shared standards, the sterilization validation requirements that underpin customer switching costs could shift in ways that affect how deeply those records are embedded in regulatory filings.
Where is this company structurally vulnerable?
If the Canadian federal government decided to shut down, decommission, or block isotope exports from the Atomic Energy of Canada Limited reactor program in Ontario, the entire chain would stop. There is no non-reactor way to make Cobalt-60 at commercial scale. Every sterilization chamber the company runs — and every chamber its competitors run — depends on that Ontario supply. Losing it would not just hurt this company; it would remove the feedstock the whole industry relies on.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped advancing and pulled back, and (2) current price is back inside or just below that zone, near the top of its recent trading range. The retest is happening at a level the stock has reached before and turned away from.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three observations describe the configuration: return on equity is elevated, debt-to-equity is high (industry-benchmarked), and the equity multiplier (Assets / Equity) is large. The DuPont identity (ROE = ROA × Equity Multiplier) means leverage mechanically amplifies whatever ROA the company is producing; the observations do not separate the two contributions.
Where is this company structurally exposed?
Three leverage observations have converged at elevated readings: debt is large relative to equity, large relative to total assets, and large relative to trailing operating cash flow. The capital structure is leveraged on three different denominators at once.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph